NORDIC: Nitric Oxide-Derived Oxidants and Regional Endothelial and Diastolic Dysfunction in Dilated Cardiomyopathy

This study has been terminated.
(safety concerns regarding use of rosiglitazone)
Sponsor:
Information provided by:
The Cleveland Clinic
ClinicalTrials.gov Identifier:
NCT00293137
First received: February 16, 2006
Last updated: September 18, 2008
Last verified: September 2008

February 16, 2006
September 18, 2008
February 2006
Not Provided
Primary Endpoint • Comparison of NO-derived oxidants, systemic ADMA, skin blood flow, forearm blood flow and exhaled NO. • Correlation of NO-derived oxidants, systemic ADMA, skin blood flow, forearm blood flow and exhaled NO to functional capacity [ Time Frame: 120 minutes ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00293137 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
NORDIC: Nitric Oxide-Derived Oxidants and Regional Endothelial and Diastolic Dysfunction in Dilated Cardiomyopathy
Nitric Oxide-Derived Oxidants and Regional Endothelial and Diastolic Dysfunction in Dilated Cardiomyopathy

The principal aim is to investigate the safety and efficacy of rosiglitazone in patients with chronic systolic heart (Dilated cardiomyopathy). We hypothesize that in patients with heart failure, rosiglitazone is safe, and can reduce nitric oxide (NO) derived oxidative stress (in particular, nitrotyrosine) thereby improving endothelial dysfunction, left ventricular performance, and metabolic parameters.

The study will be a single center, double-blind, prospective placebo controlled trial of 60 non-diabetic heart failure patients. Prior to administration of study medication, a medical history, physician exam, blood draw, laser Doppler imaging (Periscan system), venous occlusion strain gauge plethysmography, metabolic exercise stress test and 2D and 3D echocardiograms will be performed. Patients will then be randomized to receive rosiglitazone 2mg/day oral versus placebo with up-titration to 4mg/day oral versus placebo at 3 months. Each study arm will have 30 patients who will participate for 6 months. Follow up assessments will be completed at 6 weeks, 3 months and 6 months post randomization.

Observational
Not Provided
Not Provided
Not Provided
Not Provided

see inclusion/exclusion

Chronic Systolic Heart Failure (Dilated Cardiomyopathy)
Not Provided
1
Patients enrolled into the trial must have left ventricular ejection fraction of <40% by echocardiogram within 6 months of enrollment
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
60
August 2007
Not Provided

Inclusion Criteria:

Patients enrolled into the trial must meet all of the following criteria:

  1. Chronic, stable, euvolemic, heart failure optimally treated for at least 3 months with stable doses of ACE inhibitors or angiotensin-receptor blockers and beta-blockers
  2. Mild-to-moderate signs and/or symptoms of heart failure (NYHA functional Class I-II)
  3. Left ventricular ejection fraction of <40% by echocardiogram within 6 months of randomization or enrollment

Exclusion Criteria:

Patients meeting one or more of the following criteria are not eligible for randomization into the trial:

  1. Known or confirmed newly-diagnosed diabetes mellitus (2004 ADA criteria)
  2. Major cardiovascular event (myocardial infarction, unstable angina, stroke, transient ischemic attack, pulmonary embolism), or major surgery <1 month of enrollment
  3. Hospitalization or emergency room visits for heart failure exacerbation, or use of inotropic agents < 1 month
  4. NYHA class III or IV
  5. Current treatment with thiazolidinediones
  6. Allergy to rosiglitazone, or liver insufficiency (ALT > 2.5x upper limits of normal)
  7. Heart failure due to congenital heart disease, primary valvular disease, hypertrophic cardiomyopathy, or heart failure caused by known cardiotoxic agents (e.g. adriamycin)
  8. End-stage renal failure on renal replacement therapy (dialysis)
  9. Life expectancy, or expected cardiac transplantation within 12 months of enrollment
  10. Women who are pregnant, or who are planning on becoming pregnant or are lactating. Women of childbearing potential must have a negative serum pregnancy test within 48 hours prior to the time of randomization and must use contraceptive agents
  11. Unable or unwilling to consent to all components of the protocol. Patients unwilling to undergo 6-month follow-up should not be enrolled.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00293137
NORDIC
Not Provided
Anne Kanderian, MD, Cleveland CLinic
The Cleveland Clinic
Not Provided
Principal Investigator: Wilson H Tang, M.D. The Cleveland Clinic
The Cleveland Clinic
September 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP